Phase 1 (Safety and Dosage)

First-in-Human (FIH) trials traditionally begin with healthy volunteers, but when it comes to special populations—such as elderly adults, pediatric patients, or those with renal or hepatic impairment—traditional paradigms may not apply. These groups often exhibit altered pharmacokinetics, higher safety risks, or disease-specific responses. Planning a FIH study in these populations requires thoughtful balancing of scientific need, ethics, regulatory compliance, and logistical feasibility. This guide explores how to strategically design Phase 1 trials for special populations and what considerations are essential for success.
Click to read the full article.

In early-phase clinical trials, particularly those involving novel compounds or first-in-human (FIH) dosing, ensuring participant safety is paramount. A Safety Review Committee (SRC), also known as a Dose Escalation Committee or Internal Safety Monitoring Committee, is a structured body tasked with independently evaluating emerging trial safety data. Its role is to make timely, evidence-based recommendations about dose escalation, cohort progression, or trial halting. In this tutorial, we’ll explore how SRCs are formed, how they operate, and their critical contribution to Phase 1 trial governance.
Click to read the full article.

Traditional Phase 1 trials follow rigid protocols, with pre-set dose escalation and fixed cohorts. But modern drug development increasingly demands adaptive designs—flexible approaches that allow protocol changes based on real-time data without compromising participant safety or trial integrity. Adaptive designs in Phase 1 can accelerate decision-making, optimize dose selection, and reduce unnecessary exposure, especially in high-risk, complex, or innovative therapeutic programs. This article explores the concepts, benefits, risks, and implementation strategies of adaptive designs in early-phase trials.
Click to read the full article.

While often associated with large-scale Phase 3 trials, the Trial Master File (TMF) is just as critical during Phase 1. Regulatory agencies expect complete, current, and accessible documentation—even in early studies. The TMF tells the full story of a trial’s conduct, compliance, and oversight, and must be “inspection-ready at all times.” In this article, we explore what to include in your TMF from the earliest planning stages of a Phase 1 trial, who is responsible, and how to maintain quality and compliance throughout early development.
Click to read the full article.

Phase 1 clinical studies form the backbone of early drug development. These studies not only establish safety and tolerability but also generate the essential clinical pharmacology data that regulatory reviewers rely on to evaluate future clinical plans. Whether filing an Investigational New Drug (IND) application or submitting a New Drug Application (NDA), understanding what clinical pharmacology reviewers expect helps ensure your data package is complete, compliant, and actionable. This guide outlines the key expectations from regulators like the FDA, EMA, and CDSCO for Phase 1 data submissions.
Click to read the full article.

Phase 1 clinical trials are the first step in evaluating a new drug’s safety and pharmacokinetics in humans. With high-risk profiles, tight timelines, and the need for immediate response to adverse events, these studies demand efficient and accurate oversight. That’s where real-time data monitoring platforms come in. These technologies allow clinical teams to track safety labs, ECGs, PK samples, and vital signs in near real-time, enabling data-driven decisions during dose escalation, sentinel review, and protocol amendments.
Click to read the full article.

Informed consent is a cornerstone of ethical research, but in high-risk early-phase studies—especially first-in-human (FIH) trials—the stakes are elevated. These studies involve investigational agents with no prior human exposure, uncertain pharmacology, and a real possibility of serious adverse effects. Ensuring participants understand the risks and make truly informed decisions is not only a regulatory requirement—it is a profound ethical obligation. This guide outlines the practical and ethical challenges in obtaining informed consent in high-risk Phase 1 trials and offers strategies to strengthen participant comprehension and compliance.
Click to read the full article.

Phase 1 trials are especially critical in the development of cell and gene therapies (CGTs), where the risks, delivery mechanisms, and treatment goals differ significantly from traditional small molecules or biologics. These advanced therapies—ranging from CAR-T cells to viral vector gene transfers—present unique design and safety challenges. This tutorial offers a step-by-step overview of designing Phase 1 trials for CGTs, covering study structure, vector selection, immunogenicity, long-term monitoring, and regulatory expectations.
Click to read the full article.

Cardiac safety is one of the most critical parameters evaluated in Phase 1 clinical trials, especially when introducing a new chemical entity to humans for the first time. Even drugs with non-cardiac targets may affect cardiac repolarization, leading to QT interval prolongation and life-threatening arrhythmias such as torsades de pointes (TdP). That’s why intensive electrocardiogram (ECG) monitoring and QTc analysis are built into the core of early-phase study designs. This guide explains how cardiac safety is assessed in Phase 1 trials, the regulatory framework, and best practices for risk management.
Click to read the full article.

Inhalation is a preferred route of administration for respiratory conditions such as asthma, COPD, cystic fibrosis, and pulmonary infections. It offers the advantage of direct drug delivery to the lungs with rapid onset and minimal systemic exposure. However, conducting Phase 1 clinical trials for inhaled therapies requires careful planning due to challenges in dose consistency, device handling, and measurement of pulmonary pharmacokinetics (PK) and pharmacodynamics (PD). This article walks through critical design considerations, device integration, and regulatory requirements for inhaled drug development.
Click to read the full article.